Drug Channels

JULY 29, 2022

This week, I’m rerunning some popular posts while I prepare for today's live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Note that the forecasts below did not account for policy changes that could further reduce pharmaceuticals' share of U.S. healthcare spending.

Pharmacy 98

Pharmacy Drugs Government Pharmaceuticals 98

Drug Patent Watch

DECEMBER 10, 2024

from 2023 to 2030. The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48 billion in 2022 and is expected to grow at a compound annual growth rate of 5.3%

Drug Development 91

Drug Development Compliance Pharmaceutical Companies Drugs 91

The Pharma Data

NOVEMBER 1, 2021

It further evolves Boehringer Ingelheim’s commitments and significantly increases the company’s impact on health, society, and environmental issues, in alignment with the United Nations 2030 Sustainable Development Goals. Boehringer Ingelheim’s commitment to MORE GREEN is underscored by a series of initiatives.

Therapies 52

Therapies Pharmaceuticals International Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 12, 2020

Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030 sets out global targets and actions to align and re-focus the work of countries, partners and stakeholders during. 2030 road map targets. now have the consensus and the commitment of every country to work in.

Disease 52

Disease Government Treatment 52

LifeSciVC

MAY 14, 2025

Demand exceeds supply, and there is little hope in clearing the queue many ongoing studies wont even finish prior to the ISSs 2030 retirement. Access to and reliance on the ISS is a bottleneck. 6 That opportunity hasnt gone unnoticed by a burgeoning private space industry. 9 Keytruda, for example, sports a list price of $47M per kg.

Science 89

Science Production Research Drugs 89

Antidote

AUGUST 2, 2022

Not only does it impact many people today, but its prevalence is expected to double by 2030. Mitral valve regurgitation is a common kind of heart disease in the United States.

Disease 98

Disease 98

The Pharma Data

FEBRUARY 22, 2021

By 2030, Bayer aspires to reach gender parity on each individual management level. Moreover, Bayer strives to increase the proportion of people with disabilities in the workforce to more than 5 percent by 2030. In Germany, for example, it is currently 4.5

Compliance 52

Compliance Regulations Science Production 52

SCIENMAG: Medicine & Health

NOVEMBER 7, 2023

Brussels, 8 November 2023 – New international research on the economic burden of urinary incontinence reveals that the cost of continence care will reach an estimated €69.1 billion in 2023.

International 80

International Production Research 80

biobide

DECEMBER 1, 2023

Cannabis derivatives In 2022 the global legal cannabis market was valued at USD 22.1 This is forecasted to grow rapidly, with a growth rate of 25.5% A Key contributing factor to this significant growth prediction is the accelerating legalization of cannabis products and the growing acceptance of its use in the medical field and consumer goods.

Treatment 97

Treatment Production Marketing Research 97

The Pharma Data

FEBRUARY 22, 2021

By 2030, Bayer aspires to reach gender parity on each individual management level. Moreover, Bayer strives to increase the proportion of people with disabilities in the workforce to more than 5 percent by 2030. In Germany, for example, it is currently 4.5

Compliance 40

Compliance Regulations 40

The Pharma Data

MAY 31, 2022

The initiative is supported by a multidisciplinary Steering Committee of patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders from around the world, with a mission to increase global adoption of biosimilar medicines by at least 30% in 30+ countries by 2030.

Biosimilars 52

Biosimilars Treatment Government Hospitals 52

The Pharma Data

NOVEMBER 15, 2020

16, 2020 /PRNewswire/ — Diadem srl , a company developing the first blood-based test for the prediction of early onset Alzheimer’s disease, today announced that it has been selected as a finalist for both the Gaetano Marzotto Company Prize and the Gaetano Marzotto 2030 Social Impact Special Prize. . MILAN , Nov.

Disease 40

Disease Treatment Production Clinical Trials 40

SCIENMAG: Medicine & Health

JUNE 13, 2023

Although there are numerous projects from governments, NGOs, and private corporations who are committed to providing safely managed water and sanitation by 2030, a new study advocates for more holistic evaluation of water, sanitation, and hygiene (WASH) interventions. According to the study by Justin Stoler, associate […]

Government 68

Government 68

thought leadership

JUNE 4, 2024

The HTAR will take effect in January 2025 for oncology and/or advanced therapy medicinal product (ATMP) therapies, with other therapies following a staggered implementation process, including orphan drugs in 2028 and all drugs in 2030.

Therapies 59

Therapies Regulations Production Marketing 59

Agency IQ

FEBRUARY 23, 2024

NANCY SKINNER has updated a bill she introduced in early January 2024 to ban the sale of intentionally added PFAS in the state after 2030. BY WALKER LIVINGSTON, ESQ California state Sen. Although the bill may receive state support, the actual implementation of the ban, if passed, would be a herculean task.

59

59

biobide

NOVEMBER 20, 2023

projected by the year 2030. Background on the Cosmetics industry In 2022, the value of the global cosmetics market was estimated to be worth USD 262.21 billion, with an annual growth of 4.2%

Packaging 64

Packaging Regulations Production Marketing 64

Drug Target Review

SEPTEMBER 21, 2023

A novel drug, will be needful at this point as it will; help promote WHO’s roadmap for 2021-2030, provide much effective drugs and equal access to healthcare- as people living with onchocercomas will no longer worry about surgical removal of them. Visualise a society free from the inconvenience and pain associated with river blindness.

Drugs 105

Drugs Treatment Disease Research 105

Drug Target Review

SEPTEMBER 22, 2023

The substantial value of organoids is becoming increasingly recognised by supportive government initiatives developing novel drugs, with a growth rate of 22 percent between 2023 and 2030 and a market size predicted to reach over US $6.5 billion by 2030.

Clinical Research 116

Clinical Research Research Drug Development Science 116

The Pharma Data

NOVEMBER 2, 2020

Setting sights on 2030. Despite setbacks due to COVID-19, WHO will accelerate work to achieve this target by 2030. This goal is aligned with the aims of universal health coverage to leave no one behind by 2030. Infections have been brought to such low levels in some areas that 649.1

Packaging 52

Packaging Disease Treatment Drugs 52

LifeSciVC

JANUARY 16, 2024

Naturally many of these acquisitions are driven by enthusiasm for clinical-stage assets that may contribute meaningfully to revenues in 2030+, and we are seeing Pharma build deeply in several key areas (obesity, immunology, oncology, neuro) as they add on to existing franchises or build new ones.

Small Molecule 143

Small Molecule Trials Therapies Disease 143

Fierce BioTech

APRIL 30, 2025

Real-world examples will showcase how pharma organizations are integrating AI into medical affairs to drive precision and impact.

52

52

LifeSciVC

APRIL 26, 2024

Fourth, the venture exit environment circa 2027-2030 for the new crop of early stage startups being created today will likely have structural supply/demand elements more favorable than the backdrop in recent years. Fewer startups over time should ameliorate this crowding dynamic to some extent.

DNA 120

DNA Science Marketing Clinical Trials 120

DrugBank

MARCH 15, 2024

billion in 2022 and is projected to grow at a compound annual growth rate of 9.94% from 2023 to 2030. According to Grand View Research , the global weight loss and weight management market size was valued at $142.5

Pharmaceutical Companies 97

Pharmaceutical Companies Pharmaceuticals Treatment Clinical Trials 97

The Pharma Data

SEPTEMBER 16, 2020

In addition, Novartis further strengthened its carbon neutrality target to aim for full carbon neutrality across its supply chain (Scope 1, 2, 3) by 2030. Novartis recently set new ambitious targets to increase patient reach in low- and middle-income countries by 2025. Our approach to Environmental, Social and Governance topics.

Government 52

Government 52

Drug Target Review

NOVEMBER 15, 2023

The generational shift as Gen-Z enter and move up the workforce, who are expected to comprise 58 percent of the global workforce by 2030, is accelerating the introduction of these new technologies.

Pharmacokinetics 105

Pharmacokinetics International Laboratories Drugs 105

The Pharma Data

DECEMBER 15, 2020

The 2030 Consulting team provides high-caliber tactical contracting and strategic consulting for all aspects of business-to-business software solutions, from software sales and vendor selection to application development, implementation and managed services. Download the whitepaper at: [link].

Science 52

Science Compliance Regulations FDA 52

Drug Target Review

DECEMBER 4, 2023

What’s more, investment in this sector is predicted to rise by 70 percent by 2030. According to the Personalised Medicine Coalition , 34 percent of all new drugs approved by the US Food and Drug Administration (FDA) in 2022 are personalised medicines.

Treatment 105

Treatment Science DNA Doctors 105

The Pharma Data

FEBRUARY 21, 2022

The 2021–2030 NTD road map targets the prevention, control elimination and eradication of 20 diseases and disease groups by 2030.———————————————————-. in adults aged ?

Disease 52

Disease Treatment International Drugs 52

DrugBank

MARCH 7, 2024

adults using obesity medications by 2030, further underlining the growing significance of this sector. As we step into 2024, the momentum is expected to continue, with analysts projecting the weight loss drug market to reach remarkable heights, potentially hitting $100 billion by the end of the decade.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceuticals Clinical Trials Therapies 98

Fierce BioTech

SEPTEMBER 6, 2024

In the coming period, pharma should witness an ongoing transformation, as exclusivity rights to 569 medications valued at $278 billion (2022 sales) are set to expire by 2029/2030.

Marketing 52

Marketing Drugs 52

The Pharma Data

JUNE 28, 2023

AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health AstraZeneca has announced a $400 million investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030 and ensure their long-term survival.

Science 40

Science Government 40

The Pharma Data

NOVEMBER 18, 2020

With only 10 years left until 2030, the rate at which access to sanitation is increasing will need to quadruple if the world is to achieve the Sustainable Development Goal (SDG) sanitation target. The consequences of poor sanitation are devastating to public health and social and economic development. Source link.

Government 52

Government Regulations Production Treatment 52

The Pharma Data

NOVEMBER 18, 2020

developed by the human rights movement can be used to achieve sexual and reproductive health rights, and drive meaningful progress towards the fulfillment of the 2030 Agenda for Sustainable Development. . “ It explores how tactics. affecting them. .

International 52

International Research 52

The Premier Consulting Blog

MAY 4, 2023

billion in 2022 and is expected to grow approximately eight percent from 2023 to 2030 [1]. Ophthalmic drugs market size, share & trends analysis report by drug class, by disease (dry eye, glaucoma), by dosage form, by route of administration, by product type (prescription, OTC), by region, and segment forecasts, 2022-2030.

FDA 52

FDA Packaging Regulations Compliance 52

The Pharma Data

MAY 15, 2023

The Company successfully met its 2030 target to increase energy efficiency, exceeded its 2030 target to reduce total water withdrawal in areas projected to be in water stress and met its 2023 targets to train employees on compliance policies.

Government 40

Government Pharmaceuticals Compliance Production 40

The Pharma Data

MAY 4, 2021

Improving access to quality health care for 30 million people globally living in limited resource settings annually by 2030 through the Lilly 30×30 initiative. Environment (by 2030). Highlights of Lilly ‘s ESG commitments include: Access and Affordability.

Government 52

Government Disease Production 52

PPD

OCTOBER 18, 2023

Continued expansion of the biotech industry is occurring in parallel, with an estimated compound annual growth rate of 13.96% from 2023-2030. There has been an unprecedented expansion of different types of pharmaceutical therapies, as well as a change in the overall approach to health care.

Laboratories 52

Laboratories Assay Development Small Molecule Drug Development 52